Clinical trial
A Pilot Feasibility and Efficacy (Phase 2) Trial of Real Time Drug Screening and Genomic Testing to Determine an Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
NCT05057702 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Feasibility and Efficacy (Phase 2) Trial of Real Time Drug Screening and Genomic Testing to Determine an Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
- Lead sponsor
- University of California, San Francisco
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- February 22, 2022
- Completion date
- January 31, 2028
- Enrollment
- 74 (estimated)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
ependymoma, ependymoma malignant, ependymoma of brain, medulloblastoma, medulloblastoma recurrent, medulloblastoma, childhood